Despite executive orders by the Biden administration aimed to improve competition in the pharmaceutical industry, pay-for-delay deals and other antitrust issues continue to be reported. On this episode of Managed Care Cast, we speak on the history and prevalence of these anticompetitive tactics and steps to limit these deals.
In the past year, executive orders by the Biden administration have aimed to improve competition in the pharmaceutical industry by addressing pay-for-delay deals that work to prevent generics from entering the market. Although a step in the right direction, anticompetitive deals continue to be reported as the Federal Trade Commission weighs how to properly penalize involved drug companies.
On this episode of Managed Care Cast, we speak with Michael Abrams, managing partner at Numerof & Associates, on persistent barriers to entry for generics entering the pharmaceutical market, the impact of antitrust laws issued by the Biden administration, and further steps that are warranted to address anticompetitive tactics.
Listen above or through one of these podcast services:
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More